Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$41.95 -2.0%	$37.07	$16.50 ▼ $43.58	$3.74B	N/A	8,438 shs	6,168 shs
APLS Apellis Pharmaceuticals	$24.37 +0.2%	$19.47	$16.10 ▼ $41.94	$3.07B	0.78	2.90 million shs	1.34 million shs
CRMD CorMedix	$10.33 -4.4%	$12.52	$3.61 ▼ $17.43	$733.18M	1.71	2.45 million shs	8.50 million shs
PTGX Protagonist Therapeutics	$51.07 +0.2%	$53.81	$33.31 ▼ $60.60	$3.17B	2.33	640,986 shs	719,043 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.30%	+15.70%	+3.53%	+76.10%	+4,280,999,900.00%
APLS Apellis Pharmaceuticals	+2.53%	+8.91%	+36.00%	+40.64%	-27.57%
CRMD CorMedix	-9.54%	-7.37%	-4.17%	-7.29%	+174.37%
PTGX Protagonist Therapeutics	-5.32%	-5.38%	+2.54%	+18.40%	+42.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	4.7011 of 5 stars	4.3	3.0	0.0	4.4	3.7	2.5	0.6
CRMD CorMedix	3.2968 of 5 stars	4.4	1.0	0.0	0.0	3.1	0.0	1.9
PTGX Protagonist Therapeutics	2.9372 of 5 stars	3.5	3.0	0.0	0.0	3.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
APLS Apellis Pharmaceuticals	2.60	Moderate Buy	$36.83	51.14% Upside
CRMD CorMedix	2.88	Moderate Buy	$16.71	61.80% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	31.58% Upside

Current Analyst Ratings Breakdown

Latest CRMD, PTGX, AAPG, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	27.24	N/A	N/A	$0.48 per share	87.40
APLS Apellis Pharmaceuticals	$781.37M	3.94	N/A	N/A	$1.24 per share	19.65
CRMD CorMedix	$43.47M	16.12	N/A	N/A	$1.40 per share	7.38
PTGX Protagonist Therapeutics	$434.43M	7.31	$4.53 per share	11.28	$10.74 per share	4.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	N/A
CRMD CorMedix	-$17.93M	$0.22	13.77	10.99	N/A	42.11%	59.43%	44.36%	8/13/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	72.96	N/A	N/A	24.88%	8.12%	7.41%	N/A

Latest CRMD, PTGX, AAPG, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
CRMD CorMedix	N/A	4.21	3.99
PTGX Protagonist Therapeutics	N/A	16.97	17.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
APLS Apellis Pharmaceuticals	96.29%
CRMD CorMedix	34.18%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
APLS Apellis Pharmaceuticals	6.50%
CRMD CorMedix	5.30%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.25 million	N/A	N/A
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	58.95 million	Optionable

CRMD, PTGX, AAPG, and APLS Headlines

Recent News About These Companies

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8 at 12:14 PM | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8 at 9:55 AM | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7 at 5:08 AM | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7 at 2:00 AM | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6 at 6:25 PM | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6 at 4:05 PM | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5 at 3:55 AM | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

Jupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

GSA Capital Partners LLP Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Envestnet Asset Management Inc.

August 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 1, 2025 | marketbeat.com

Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Royce & Associates LP Makes New $593,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

July 30, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $570,533.70 in Stock

July 29, 2025 | marketbeat.com

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 10,415 Shares of Stock

July 29, 2025 | insidertrades.com

Skandinaviska Enskilda Banken AB publ Sells 61,700 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

July 27, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 138,406 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

July 27, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

July 26, 2025 | marketbeat.com

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 12,859 Shares of Stock

July 24, 2025 | marketbeat.com

Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

July 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, PTGX, AAPG, and APLS Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$41.95 -0.86 (-2.01%)

As of 03:59 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Apellis Pharmaceuticals NASDAQ:APLS

$24.37 +0.04 (+0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$23.70 -0.68 (-2.77%)

As of 07:49 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

CorMedix NASDAQ:CRMD

$10.33 -0.48 (-4.44%)

Closing price 04:00 PM Eastern

Extended Trading

$10.36 +0.03 (+0.29%)

As of 07:55 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Protagonist Therapeutics NASDAQ:PTGX

$51.07 +0.11 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$50.60 -0.48 (-0.93%)

As of 05:46 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time